Carfilzomib, the endothelium & the complement threshold
Proteasome-inhibitor thrombotic microangiopathy
Weeks into carfilzomib, the microvascular endothelium — often already primed by a silent complement-regulator gene deletion — tips into thrombotic microangiopathy: schistocytes and falling platelets, an acute kidney injury the drug set in motion, and an ADAMTS13 that comes back normal because this was never TTP.
- 17.97
- FAERS reporting odds ratioCarfilzomib's disproportionate thrombotic-microangiopathy signal in the FDA FAERS database (2004–2023), far above every other proteasome inhibitor (95% CI 15.04–21.47)
- 88%
- of PI-TMA is carfilzomib101 of 115 proteasome-inhibitor TMA cases across 44 studies were attributed to carfilzomib — the dominant culprit of the class
- 5.2%
- single-center incidenceTMA in 5 of 96 consecutive myeloma patients on carfilzomib, concentrated at high dose (≥56 mg/m²); the authors argue the complication is under-recognized
- 21 days
- median time to onsetFrom proteasome-inhibitor initiation to TMA diagnosis in the founding multi-center series (range 5 days to 17 months)
- 94%
- TMA resolves off-drugHematologic resolution after carfilzomib withdrawal in the largest series (37 cases) — but 44% were still left with KDIGO stage-3 acute kidney injury at discharge
Teaching case · illustrative composite, not a real patient
A 64-year-old man with relapsed multiple myeloma, three weeks into carfilzomib–lenalidomide–dexamethasone at the 56 mg/m² dose, is admitted with fatigue, a blood pressure of 176/102, and dark urine. Labs show hemoglobin 7.6 g/dL, platelets 22 ×10⁹/L, LDH 690 U/L, undetectable haptoglobin, and schistocytes on the smear; creatinine has risen from 1.0 to 3.1 mg/dL with new proteinuria.
The microangiopathic hemolysis with thrombocytopenia and acute kidney injury raises TTP, and empiric plasma exchange is begun — but ADAMTS13 activity returns normal, excluding TTP, and a work-up for Shiga-toxin infection is negative. Recognizing drug-induced TMA, the team stops carfilzomib. Because the kidney injury is severe and dialysis-requiring, terminal complement blockade with eculizumab is added; a complement work-up later returns a homozygous CFHR3–CFHR1 deletion. Over several weeks the hemolysis abates and the platelet count recovers, and he is eventually able to come off dialysis — though his baseline creatinine does not fully return.
Teaching point — Proteasome-inhibitor TMA — overwhelmingly a carfilzomib complication — presents weeks into therapy as microangiopathic hemolysis, thrombocytopenia, and acute kidney injury that mimics TTP. The distinguishing test is a NORMAL ADAMTS13, which excludes TTP and redirects management away from indefinite plasma exchange. The cornerstone is stopping the drug; many cases carry an underlying complement alternative-pathway defect, and terminal complement (anti-C5) blockade is the rescue for severe, dialysis-requiring, or plasma-exchange–refractory disease.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
How we learned it
- 2008
Morita and colleagues report thrombotic microangiopathy after bortezomib (with dexamethasone) in a patient with multiple myeloma.
An early historical anchor for proteasome-inhibitor TMA — predating carfilzomib's approval and hinting that the class, not one drug, could injure the microvasculature.
PMID 18636313 - 2014
Hobeika, Self, and Velez publish a kidney-biopsy–confirmed case of carfilzomib-associated renal thrombotic microangiopathy with concurrent podocytopathy.
One of the first biopsy-proven reports tying the newly approved carfilzomib to intrarenal TMA, with proteinuria and hypertension improving about eight weeks after the drug was stopped.
PMID 25267524 - 2015
Al-Nouri, George, and colleagues publish the reference systematic review of drug-induced TMA, cataloguing which drugs carry definite causal evidence.
Provided the framework — 'is this drug-induced TMA?' — into which the emerging carfilzomib reports would be slotted, and set the evidentiary bar for causation.
PMID 25414441 - 2016
Yui et al. assemble 11 patients from six centers worldwide with proteasome-inhibitor–associated TMA (bortezomib and carfilzomib).
The founding multi-center series that established PI-TMA as a real entity, fixed its roughly 21-day median onset, and showed most cases resolve after drug withdrawal.
PMID 27286661 - 2021
Blasco et al. show that acute-phase plasma from carfilzomib-TMA patients deposits the C5b-9 membrane-attack complex on cultured endothelial cells.
Named complement overactivation as the enabler of the endothelial injury, providing the biologic rationale that would make terminal complement blockade the rescue therapy.
PMID 32469083 - 2023
Moscvin et al. find germline alternative-complement-pathway deletions (delCFHR3–CFHR1, delCFHR1–CFHR4) enriched in myeloma patients who develop carfilzomib-TMA versus carfilzomib-exposed controls.
Reframed carfilzomib-TMA as a two-hit disease — an inherited complement-regulator defect that lowers the threshold for the drug to trigger microangiopathy.
PMID 36849497 - 2024
Joseph, Coppo, and the French national reference center report the largest carfilzomib-TMA series — 37 cases.
Defined the outcome landscape at scale: near-universal acute kidney injury, ~94% hematologic resolution but frequent residual renal impairment, and no clear benefit from plasma exchange, steroids, or eculizumab once the drug was stopped.
PMID 38658194 - 2025
Deng, Wang, and Wang mine the FDA FAERS database (2004–2023) and a pooled case cohort to quantify carfilzomib's TMA signal.
Put a pharmacovigilance number on the class effect — a carfilzomib TMA reporting odds ratio of 17.97, dwarfing other proteasome inhibitors — with a pooled median onset of about 8 days.
PMID 39939437
The landmark studies
Proteasome inhibitor associated thrombotic microangiopathy
Yui JC, et al. · Am J Hematol 2016 · PMID 27286661
The founding series establishing proteasome inhibitors (bortezomib and carfilzomib) as a cause of drug-induced TMA, defining its subacute onset and its tendency to resolve after the drug is withdrawn.
11 patients from 6 medical centers worldwide; median time from PI initiation to TMA 21 days (range 5 days to 17 months); at diagnosis median hemoglobin 7.5 g/dL, platelets 20 ×10⁹/L, LDH 698 U/L, creatinine 3.12 mg/dL; 9 of 11 resolved without further hemolysis after PI withdrawal, 2 had persistent hemolysis, and 1 recurred on PI rechallenge.
Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes
Joseph A, et al. (Coppo P, senior) · Nephrol Dial Transplant 2024 · PMID 38658194
The largest carfilzomib-TMA series to date: near-universal, often severe acute kidney injury that resolves hematologically in most but leaves frequent renal sequelae — and plasma exchange, steroids, and eculizumab showed no significant impact on outcome once the drug was stopped.
37 cases; a trigger identified in more than half (8 influenza, 5 SARS-CoV-2); acute kidney injury in 100% (KDIGO stage 3 in 31/37, 84%); neurologic involvement 36%, cardiac 19%; TMA resolved in most (34, 94%) but 44% still had stage-3 AKI at discharge; plasma exchange 51%, steroids 38%, eculizumab 50% — none significantly altering outcomes.
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy
Blasco M, et al. · Br J Haematol 2021 · PMID 32469083
Directly implicated the terminal complement pathway: acute-phase plasma from carfilzomib-TMA patients drove membrane-attack-complex (C5b-9) deposition on cultured endothelial cells, providing the biologic rationale for anti-C5 therapy.
C5b-9 endothelial deposition was positive with acute-phase patient plasma in 3 of 4 patients tested.
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Moscvin M, et al. · Blood Cancer J 2023 · PMID 36849497
Germline alternative-complement-pathway deletions were enriched in patients who developed carfilzomib-TMA versus carfilzomib-exposed controls — evidence that inherited complement dysregulation predisposes to the endothelial injury.
10 carfilzomib-TMA cases versus 10 matched carfilzomib-exposed non-TMA controls; a higher frequency of delCFHR3–CFHR1 and delCFHR1–CFHR4 deletions in cases than in controls and the general population.
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review
Chen C, et al. · Blood Cancer J 2024 · PMID 39511171
Synthesized the published PI-TMA experience, confirming carfilzomib as the overwhelmingly dominant culprit and cataloguing how cases have been treated.
115 PI-TMA cases across 44 studies; carfilzomib implicated in 101 of 115 (88%); treatment was supportive care in 28, therapeutic plasma exchange in 43, eculizumab alone in 9, and plasma exchange plus eculizumab in 13, with complete remission reported in 7 plasma-exchange–refractory cases given eculizumab.
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis
Deng Z, Wang S, Wang C · Support Care Cancer 2025 · PMID 39939437
Quantified the class effect in real-world reporting: proteasome inhibitors carry a TMA signal driven overwhelmingly by carfilzomib, with a short median time to onset and near-universal AKI in pooled cases.
FAERS (2004–2023): 225 TMA cases in 213 PI-exposed individuals; PI overall reporting odds ratio 1.71 (1.49–1.96); carfilzomib in 58.7% of exposed individuals (125 of 213), ROR 17.97 (15.04–21.47); a pooled cohort of 60 cases (35 studies) had median age 63, 61.7% male, median onset 8 days, hemolytic anemia 98.1%, thrombocytopenia 96.6%, AKI 96.7%, with hematologic recovery in 96.3% and renal recovery in 93.3%.
What the data says now
How disproportionately each agent's FAERS reports name these phenotypes vs. all other drugs (reporting odds ratio; significant signals only, 95% CI lower bound > 1; as of 2026-07-10). A reporting signal, not incidence or proven causation.
| Agent | TMA |
|---|---|
| Carfilzomib | Carfilzomib, Thrombotic Microangiopathy: ROR 29.33, 566 reports |
| Bortezomib | Bortezomib, Thrombotic Microangiopathy: ROR 4.63, 293 reports |
Carfilzomib share of all proteasome-inhibitor TMA
Systematic review across 44 studies
PMID 39511171Single-center incidence of carfilzomib-induced TMA
Consecutive myeloma patients on carfilzomib, mostly high-dose (≥56 mg/m²)
PMID 35373680FAERS thrombotic-microangiopathy reporting odds ratio, carfilzomib
FDA FAERS pharmacovigilance database, 2004–2023
PMID 39939437Incidence before vs after a mitigation protocol
Newly diagnosed myeloma on the prospective CARDAMON trial (step-up dosing, hypertension control, dexamethasone premedication)
PMID 33650100Time from proteasome-inhibitor start to TMA
Founding multi-center series of 11 PI-TMA patients
PMID 27286661How it's managed
- 1
Stop the proteasome inhibitor — the cornerstone
Discontinuation is the essential first step; hematologic TMA resolves in the large majority (about 94% in the largest series), though the acute kidney injury frequently leaves residual impairment, so renal recovery lags and may be incomplete.
Largest retrospective series (37 cases); consistent across cohorts · PMID 38658194
- 2
Check ADAMTS13 to exclude TTP before committing to plasma exchange
ADAMTS13 activity is normal in most proteasome-inhibitor TMA, distinguishing it from TTP; a normal result argues against the ongoing plasma exchange that TTP requires and refocuses care on drug withdrawal and complement-directed options.
Pooled case analysis — ADAMTS13 normal in about 62% (41 of 66) · PMID 38728883
- 3
Reserve terminal complement (anti-C5) blockade for severe or refractory disease
Given the complement-driven mechanism, eculizumab is the rescue for severe, dialysis-requiring, or plasma-exchange–refractory cases; a scoping review of eculizumab in drug-induced TMA (carfilzomib cases included) reported renal recovery in about 80% and complete hematologic recovery in about 74%.
Scoping review, 69 drug-induced TMA cases; supported by refractory carfilzomib case reports · PMID 36871347
- 4
Do not expect plasma exchange or steroids to change the trajectory
In the largest series, plasma exchange, corticosteroids, and even eculizumab showed no significant impact on outcome once the drug was stopped — underscoring that timely proteasome-inhibitor withdrawal, not reflexive plasma exchange, is what drives recovery.
Retrospective series (37 cases) — no treatment significantly altered outcomes · PMID 38658194
- 5
If rechallenge is needed, use a reduced dose and monitor closely
Because the injury is dose-related, a reduced-dose carfilzomib rechallenge has been tolerated without TMA recurrence while preserving disease control — an option when the proteasome inhibitor remains the best anti-myeloma choice, undertaken with close hematologic and renal monitoring.
Case report — reduced-dose rechallenge without recurrence · PMID 36653134
What the guidelines say
Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.